St. Jude Medical seesaws on FDA warning letter

January 15, 2013 by MassDevice staff

Wall Street investors send shares of St. Jude Medical up yesterday and down today after the company reveals a warning letter from the FDA over its Sylmar, Calif., Durata defibrillator lead plant. Wall Street Beat

A warning letter from the FDA to St. Jude Medical (NYSE:STJ) sent the St. Paul, Minn.-based medical device company's stock on a seesaw ride yesterday and today.

STJ shares closed up 1.5% yesterday at $38.85 each after St. Jude revealed the warning letter, but closed down 1.2% today at $38.39 apiece.


Get the complete picture with a MassDevice Plus membership. Registered users can login here.